These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30209444)

  • 1. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
    Cross G
    Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
    Bourgoin A
    Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Generic Medicines Association (EGA)--16th Annual Conference.
    Kennedy B
    IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicines for Europe - 16th Legal Affairs Conference (June 29-July 1, 2022 - Barcelona, Spain).
    Tumminello M
    Drugs Today (Barc); 2022 Sep; 58(9):457-462. PubMed ID: 36102906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence Europe 2017. London, UK - February 22-23, 2017.
    Kibble A
    Drugs Today (Barc); 2017 Mar; 53(3):203-207. PubMed ID: 28447077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A report from CPhI Worldwide 2013, Fifth Annual Pre-Connect Conference (October 22-24, 2013 - Frankfurt, Germany).
    Kuhrt K; Gilpatrick J
    Drugs Today (Barc); 2013 Nov; 49(11):745-50. PubMed ID: 24308020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
    Tu SS; Sarpatwari A
    N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
    [No Abstract]   [Full Text] [Related]  

  • 13. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
    Kuhrt K
    IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
    [No Abstract]   [Full Text] [Related]  

  • 16. Generics and Biosimilars: Barriers and Opportunities.
    Scheckel CJ; Rajkumar SV
    Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
    [No Abstract]   [Full Text] [Related]  

  • 17. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of biosimilars in an era of oncologic drug shortages.
    Li E; Subramanian J; Anderson S; Thomas D; McKinley J; Jacobs IA
    Drug Des Devel Ther; 2015; 9():3247-55. PubMed ID: 26150698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Western European markets for biosimilar and generic drugs: worth differentiating.
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Sep; 16(7):683-7. PubMed ID: 25791078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.